Injectable opioid agonist therapy, extended-release agonists, and antagonists are beyond the scope of this guideline. "The management of opioid use disorder is a rapidly changing and ever-evolving ...

Opioid agonist therapy (OAT) involves taking medications like buprenorphine, buprenorphine-naloxone, or methadone to treat opioid use disorder. These medications reduce cravings for opioids and help ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

Opioid-related neurocognitive symptoms among patients on long-term opioid therapy were most prevalent during the course of ...

The latest volunteer-run overdose prevention site to open is outside North Island Hospital Comox Valley on Vancouver Island.

and willingness to continue opioid therapy. A literature search identified more than a dozen published reports on the use of pure opioid antagonists (naloxone, naltrexone, methylnaltrexone ...

App users also stayed with their opioid agonist therapy an average 290 days, compared with 236 days for those who only got medication, the study says. “These results are promising, and they ...

Morphine is a full opioid agonist and is relatively selective for ... need for access to naloxone when initiating and renewing therapy. Consider prescribing naloxone based on risk factors for ...

Cebranopadol reduced pain intensity in patients following abdominoplasty surgery in the ALLEVIATE-1 clinical trial.

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. | Tris Pharma has pointed to a phase 3 win for its pain ...

who may not have been successful with treatment or other addiction therapies such as oral opioid agonist therapy (OAT) and other appropriate empirically supported services. The project will identify ...